Why Pfizer, Walt Disney, Delek Logistics, and Inter are Facing Analyst Downgrades The stock market is constantly changing, and sometimes analysts revise their ratings on certain stocks based on new information or expectations. In this blog post, we will look at four big analyst downgrades that happened recently and what they mean for investors. Pfizer: Neutral from Outperform Pfizer (NYSE:PFE) is one of the leading pharmaceutical companies in the world, and it has been in the spotlight for its COVID-19 vaccine. However, Credit Suisse downgraded Pfizer to Neutral from Outperform and lowered its price target to $40.00 from $47.00, citing limited pipeline catalysts and uncertainty. The firm said that Pfizer’s recent updates on its oncology and rare disease programs were disappointing and that its growth prospects beyond 2022 are unclear. Credit Suisse also reduced its earnings estimates for Pfizer, reflecting lower revenue assumptions and higher expenses. Pfizer’s stock has be...